Novo Nordisk responded today to the U.S. Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to prevent competition and raise prices. Related Content Wegovy sales more than doubled as the weight loss drug boom keeps powering Novo Nordisk Ozempic is so hot right now that subsidies for the drug are being cut in Novo Nordisk's home country Wegovy and Ozempic: Are we ready for weight loss drugs? CC Share Subtitles Off English Share this Video Facebook Twitter Email Reddit Link